KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EPS (Basic) (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed EPS (Basic) for 16 consecutive years, with -$0.24 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) fell 136.36% year-over-year to -$0.24, compared with a TTM value of $1.82 through Dec 2025, down 19.11%, and an annual FY2025 reading of $1.82, down 19.11% over the prior year.
  • EPS (Basic) was -$0.24 for Q4 2025 at Biomarin Pharmaceutical, down from -$0.16 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.25 in Q2 2025 and bottomed at -$0.32 in Q4 2021.
  • Average EPS (Basic) over 5 years is $0.27, with a median of $0.18 recorded in 2022.
  • The sharpest move saw EPS (Basic) plummeted 455.56% in 2021, then skyrocketed 1200.0% in 2023.
  • Year by year, EPS (Basic) stood at -$0.32 in 2021, then soared by 96.88% to -$0.01 in 2022, then surged by 1200.0% to $0.11 in 2023, then surged by 500.0% to $0.66 in 2024, then plummeted by 136.36% to -$0.24 in 2025.
  • Business Quant data shows EPS (Basic) for BMRN at -$0.24 in Q4 2025, -$0.16 in Q3 2025, and $1.25 in Q2 2025.